These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 6139285)

  • 41. Differential effects of haloperidol decanoate, a long-acting neuroleptic, in behavioral and biochemical tests.
    Oka M; Karasawa T; Ochi Y; Asano K; Terauchi Y; Kadokawa T
    Arch Int Pharmacodyn Ther; 1985 Oct; 277(2):289-302. PubMed ID: 4062440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
    Meller E
    Psychopharmacology (Berl); 1982; 76(3):222-7. PubMed ID: 6808540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.
    Prosser ES; Pruthi R; Csernansky JG
    Psychopharmacology (Berl); 1989; 99(1):109-16. PubMed ID: 2506596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A permanent dopamine receptor up-regulation in the ovariectomized rat.
    Gordon JH; Fields JZ
    Pharmacol Biochem Behav; 1989 May; 33(1):123-5. PubMed ID: 2780771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide.
    Hassan MN; Reches A; Kuhn C; Higgins D; Fahn S
    Clin Neuropharmacol; 1986; 9(1):71-8. PubMed ID: 3829008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

  • 48. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacology of fluperlapine compared with clozapine.
    Eichenberger E
    Arzneimittelforschung; 1984; 34(1A):110-3. PubMed ID: 6145425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
    Fayle P; Jackson DM; Jenkins OF; Lafferty PA
    Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Failure of chronic haloperidol to affect prolactin secretion due to acute haloperidol administration.
    Parati EA; Parenti M; Locatelli V; Penalva A; Tamminga C; Müller EE
    Pharmacol Res Commun; 1985 May; 17(5):407-15. PubMed ID: 4034625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
    Koller W; Curtin J; Fields J
    Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotypic influences on striatal dopaminergic regulation in mice.
    Severson JA; Randall PK; Finch CE
    Brain Res; 1981 Apr; 210(1-2):201-15. PubMed ID: 6261873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity.
    Ben-Shachar D; Youdim MB
    J Neurochem; 1990 Apr; 54(4):1136-41. PubMed ID: 1968955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Age alters dopaminergic responses to estradiol.
    Roy EJ; Sheinkop S; Wilson MA
    Eur J Pharmacol; 1982 Aug; 82(1-2):73-5. PubMed ID: 6889971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
    Meller E; Friedman E
    Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.